LAUSR

REFERENCES 1. Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394 (10192):29-38. 2. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International staging system for multiple myeloma: a report from International myeloma working group. J Clin Oncol. 2015;33:2863-2869. 3. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412-3420. 4. Malavasi F, Funaro A, Roggero S, Horenstein A, Calosso L, Mehta K. Human CD38: a glycoprotein in search of a function. Immunol Today. 1994;15:95-97. 5. Malavasi F, Caligaris-Cappio F, Milanese C, Dellabona P, Richiardi P, Carbonara AO. Characterization of a murine monoclonal antibody specific for human early lymphohemopoietic cells. Hum Immunol. 1984;9:9-20. 6. Xu XS, Dimopoulos MA, Sonneveld P, et al. Pharmacokinetics and exposure-response analyses of Daratumumab in combination therapy regimens for patients with multiple myeloma. Adv Ther. 2018;35:18591872.